Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Alkynes Stories

2008-11-07 12:00:23

Genentech, a biotechnology company, and OSI Pharmaceuticals, have announced that a global Phase III study has met its primary endpoint and showed that Tarceva significantly extended the time patients with advanced non-small cell lung cancer lived without their cancer getting worse when given immediately following initial treatment with platinum-based chemotherapy, compared to placebo. Saturn is a placebo-controlled, randomized, double-blind, Phase III study conducted by Roche that enrolled...

2008-11-07 03:00:04

Genentech, Inc. (NYSE:DNA) and OSI Pharmaceuticals, Inc. (Nasdaq:OSIP) today announced that a global Phase III study (SATURN) met its primary endpoint and showed Tarceva(R) (erlotinib) significantly extended the time patients with advanced non-small cell lung cancer (NSCLC) lived without their cancer getting worse when given immediately following initial treatment with platinum-based chemotherapy, compared to placebo. There were no new or unexpected safety signals in the study and adverse...

2008-10-27 09:00:41

Ardea Biosciences, Inc. (Nasdaq:RDEA) announced today that additional data from a Phase 2a monotherapy study of RDEA806, our lead non-nucleoside reverse transcriptase inhibitor (NNRTI) in development for the treatment of human immunodeficiency virus (HIV), were presented at the 48th Annual ICAAC/IDSA 46th Annual Meeting in Washington, DC. Dr. Graeme Moyle, Director of HIV Research, Chelsea and Westminster Hospital, gave an oral presentation showing that in the Phase 2a study, RDEA806...

2008-10-23 15:00:28

U.S. scientists say an early trial of a multi-kinase inhibitor has shown impressive tumor shrinkage in patients with a hard-to-treat form of thyroid cancer. Assistant Professor Pasi Janne of Harvard University Medical School and Professor Steven Sherman of the M.D. Anderson Cancer Center said the encouraging results have put the drug's development on a fast track, prompting the accelerated initiation of a large phase III trial. The compound, XL184, targets cell growth and migration, as...

2008-10-20 09:00:42

Ardea Biosciences, Inc. (Nasdaq:RDEA) announced today that the United States Patent and Trademark Office has issued a patent covering the composition of matter of RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of patients with human immunodeficiency virus (HIV), and related analogs. U.S. Patent No. 7,435,752 was issued on October 14, 2008. "We are very pleased with the continued expansion of our proprietary position in the NNRTI area....

2008-10-12 18:00:07

A GRANDMOTHER with terminal cancer who faced moving to get life- saving drugs on the NHS has won her battle with Midland health bosses to receive her medication. Carol Rummels, from Stoke Lodge, in Bristol, considered moving to Scotland so she could continue to take the drug Tarceva. Doctors had given the 61 year-old just two months to live after diagnosing with brain and lung cancer last summer. But after taking the drug the tumours shrank, prolonging her life by another 12 months....

2008-10-12 18:00:07

A GRANDMOTHER with terminal cancer who faced moving to Scotland to get life-saving drugs free on the NHS has won her battle with health bosses in England to fund the medication that is keeping her alive. The landmark ruling means that other cancer sufferers in the area that may benefit from the drug will now be given Tarceva on the NHS. Carol Rummels, from Stoke Lodge, in Bristol, was given just two months to live after being diagnosed with brain and lung cancer last summer but after...

2008-10-08 09:00:51

CORONA, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that investigators presented clinical pharmacokinetic data on oxybutynin chloride topical gel (OTG), its investigational therapy for overactive bladder (OAB). Previously, the efficacy and safety of OTG were demonstrated in a Phase 3 multi-center, double blind, placebo-controlled study. The study showed that daily treatment of a 1g dose of OTG for 12...

2008-10-06 09:00:09

Genentech and OSI Pharmaceuticals have announced that a randomized Phase III study evaluating Avastin in combination with Tarceva in patients with advanced non-small cell lung cancer whose disease had progressed following platinum-based chemotherapy did not meet its primary endpoint of improving overall survival compared to Tarceva in combination with placebo. However, there was clear evidence of clinical activity with improvements in the secondary endpoints of progression-free survival and...

2008-10-06 03:00:07

Genentech, Inc. (NYSE:DNA) and OSI Pharmaceuticals, Inc. (Nasdaq:OSIP) today announced that a randomized Phase III study (BeTa Lung) evaluating Avastin(R) (bevacizumab) in combination with Tarceva(R) (erlotinib) in patients with advanced non-small cell lung cancer (NSCLC) whose disease had progressed following platinum-based chemotherapy did not meet its primary endpoint of improving overall survival compared to Tarceva in combination with placebo. However, there was clear evidence of...